KRAS, HER2 & ALK: targeted options and sequencing issues - memoinOncology
Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
SUMMIT (PUMA-NER-5201) Basket Trial
Targeting HER2 genomic alterations in non-small cell lung cancer - ScienceDirect
Neratinib-based combination therapy in HER2-Mutant lung cancer | VJOncology
PUMA Background
Neratinib Chapter
SUMMIT (PUMA-NER-5201) Basket Trial
Thoracic Oncology Translational Research
Full article: Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations
208051Orig1s000
208051Orig1s000
Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
Reunion Puma and Da Vinci - gut-aiderbichl.com
SUMMIT (PUMA-NER-5201) Basket Trial
EDGAR Filing Documents for 0001437749-22-000622
Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
Thoracic Oncology Translational Research
SUMMIT (PUMA-NER-5201) Basket Trial
Thoracic Oncology Translational Research
Effective Management and Prevention of Neratinib-Induced Diarrhea
ADCs Showcase Impressive Activity, Second-Line Combos Seek to Raise the Bar in Quest to Target HER2+ NSCLC
